Introduction

Iwona Hus

Vol 12, Supp. D (2021)

Editorial

Midostaurin in the treatment of patient with acute myeloid leukemia with FLT3-TKD mutation and NPM1 mutation

Aleksander Salomon-Perzyński, Urszula Walczak, Kinga Kos-Zakrzewska, Ewa Lech-Marańda, Bożena Katarzyna Budziszewska

Vol 12, Supp. D (2021)

Case report

Effectiveness of combined therapy with midostaurin and standard chemotherapy and high dose chemotherapy with allogeneic stem cell transplantation in high risk acute myeloid leukemia with FLT3-TKD and NPM1 mutations

Elżbieta Patkowska, Monika Prochorec-Sobieszek, Ewa Lech-Marańda, Barbara Nasiłowska-Adamska

Vol 12, Supp. D (2021)

Case report

Midostaurin added to standard therapy in FLT3-positive acute myeloid leukemia treatment

Andrzej Szczepaniak, Zuzanna Rzetelska

Vol 12, Supp. D (2021)

Case report

Treatment of a patient with acute myeloid leukemia with FLT3-ITD mutation

Katarzyna Jerzmanowska, Agnieszka Pluta

Vol 12, Supp. D (2021)

Case report

Difficulties in the management of a patient with acute myeloid leukaemia and high mutant allelic ratio FLT3-ITD — refractoriness to the standard induction therapy along with midostaurin

Elżbieta Patkowska, Joanna Sawczuk-Chabin, Iwona Solarska, Katarzyna Borg, Ewa Lech-Marańda

Vol 12, Supp. D (2021)

Case report